# Long-term Safety of Protopic in Atopic Eczema

> **NCT00560378** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 789 (actual)

## Conditions studied

- Dermatitis, Atopic
- Eczema, Atopic

## Interventions

- **DRUG:** Tacrolimus ointment 0.1%

## Key facts

- **NCT ID:** NCT00560378
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-06
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** 789 (ACTUAL)
- **Last updated:** 2014-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00560378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00560378, "Long-term Safety of Protopic in Atopic Eczema". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00560378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*